Is Tesofensine a Peptide? No, and the Difference Matters
Roughly 2,800 people a month search for the phrase tesofensine peptide. The phrase is wrong, and the reason it is so common is worth understanding, because the mistake carries real consequences for how the drug is taken and who should avoid it.
6 min read · Updated August 27, 2026
Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC. Last reviewed August 27, 2026.Quick Answer
No. Tesofensine is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor (developed as NS-2330), a tropane derivative with no amino acid chain and no amide backbone. It is taken orally as a capsule, where most therapeutic peptides must be injected, and it raises blood pressure and heart rate, so it carries cardiovascular contraindications that peptides do not. The “peptide” label comes from where it is sold, since unapproved compounds are stocked by peptide and research-chemical storefronts, not from what it is.
What tesofensine actually is
Tesofensine, developed under the code NS-2330, is a tropane-derived small molecule. It works by inhibiting the reuptake transporters for three neurotransmitters at once, dopamine, noradrenaline and serotonin, which is why it is described as a triple monoamine reuptake inhibitor.
A peptide is defined structurally: a chain of amino acids linked by amide bonds. That definition is what makes BPC-157 a peptide at 1,419 daltons and semaglutide a peptide at considerably more. Tesofensine has no such chain. The classification is not a matter of opinion or convention, it is a matter of what the molecule is built from.
It was originally investigated for Parkinson’s disease and Alzheimer’s. It did not perform well in either. The weight loss observed incidentally in those trials is what redirected it toward obesity, where Phase IIb produced 9.2 percent weight loss at 0.5 mg over 24 weeks before development stopped.
Where the wrong label came from
The label is an artifact of distribution. Because tesofensine has no FDA approval, no retail pharmacy stocks it. The vendors that do carry unapproved compounds are overwhelmingly peptide storefronts and research-chemical suppliers, so tesofensine sits in a catalog next to BPC-157 and CJC-1295 and inherits the category name of its shelf.
You can watch this happen in the search results. A page currently ranking on the first page of Google for the buy query is titled Buy Tesofensine Peptide Capsules Online. Other listings sell it as “research tablets”, and at least one marketplace listing spells the product name with a currency symbol to get past filtering. Each of those is a labelling decision made for commercial reasons, and the search volume follows the labels people encounter.
The result is roughly 2,800 monthly searches for a phrase that describes nothing real, and a large number of buyers who have categorised the drug incorrectly before they ever take it.
Why the category error has consequences
If this were only terminology, it would not be worth a page. It changes three things that affect how the drug is used.
| Dimension | A therapeutic peptide | Tesofensine |
|---|---|---|
| Structure | Amino acid chain, amide bonds | Tropane-derived small molecule, no amino acid chain |
| Route | Usually injected, degraded in the gut | Orally active, dispensed as a 500 mcg capsule |
| Mechanism | Binds a receptor to send a signal | Blocks monoamine reuptake transporters in the CNS |
| Cardiovascular screening | Not typically required for recovery or GH peptides | Required. Raises blood pressure and heart rate |
| Psychiatric effects | Rare | Mood changes in 10 to 15 percent, more above 0.5 mg |
The row that does damage is the fourth. Someone who has filed tesofensine as “a weight loss peptide” carries over a set of expectations from BPC-157 or CJC-1295, where the safety conversation is mild and the main question is dosing. Tesofensine has absolute contraindications: uncontrolled hypertension, cardiovascular disease, a history of stroke, anxiety disorders, and concurrent MAOI use. The category error is exactly what makes someone skip that check. See the full side effect profile.
What to call it instead
- Accurate: triple monoamine reuptake inhibitor, small-molecule appetite suppressant, NS-2330.
- Close enough in conversation: a non-GLP-1 oral weight loss medication, or stimulant-adjacent appetite suppressant.
- Wrong: tesofensine peptide, weight loss peptide, GLP-1, SARM.
One further name to keep separate: tesamorelin. That one genuinely is a peptide, a GHRH analog used for visceral fat, and it is a component of the Lean Stack. The two names look alike and are routinely swapped, including in published content. They are unrelated molecules with different routes, mechanisms and risks.
Bottom line
Tesofensine is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor, taken orally, with a cardiovascular screening requirement no peptide in a standard catalog carries. The label is a product of the storefronts that sell it. If you are considering it, the useful reclassification is not “peptide” but “a prescription CNS drug that needs a blood pressure check first”.
For the clinical protocol and trial data, read the tesofensine protocol guide. For the safety profile, read tesofensine side effects. For how it is legitimately obtained, read where to buy tesofensine.
Common questions about tesofensine and peptides
- Is tesofensine a peptide?
- No. Tesofensine is a small-molecule triple monoamine reuptake inhibitor, a tropane derivative developed as NS-2330. A peptide is a chain of amino acids joined by amide bonds. Tesofensine has no amino acid chain and no amide backbone, so it does not meet the definition by structure. It is closer in chemical family to other tropane-derived CNS drugs than to anything in a peptide catalog.
- Why is tesofensine called a peptide then?
- Because of where it is sold, not what it is. Tesofensine is not FDA approved, so it is not stocked at retail pharmacies, and the storefronts that carry unapproved compounds are largely peptide vendors and research-chemical suppliers. Those sellers list it alongside actual peptides and title their listings accordingly. One page currently ranking on the first page of Google for the buy query is literally titled "Buy Tesofensine Peptide Capsules Online". The label is a marketing artifact of the sales channel.
- Does it matter whether tesofensine is a peptide?
- Yes, in three practical ways. Route: tesofensine is orally active and taken as a capsule, where most therapeutic peptides are degraded in the gut and must be injected. Mechanism: it blocks the reuptake transporters for dopamine, noradrenaline and serotonin, a central nervous system drug action, rather than binding a receptor to send a signal the way peptides do. Screening: it raises blood pressure and heart rate, so it carries cardiovascular contraindications that recovery and growth-hormone peptides simply do not. Someone who files it mentally as "just another peptide" will skip exactly the screening that matters.
- What class of drug is tesofensine?
- A triple monoamine reuptake inhibitor, sometimes written TRI. It inhibits the reuptake of dopamine, noradrenaline and serotonin at once, so more of each stays available in the synapse. It was originally investigated for Parkinson's disease and Alzheimer's, where it underperformed, and the weight loss seen in those trials is what redirected it toward obesity. Its closest functional relatives are appetite-suppressing stimulants, not peptides.
- Is tesofensine taken by injection?
- No. It is orally active and dispensed as a capsule, which is one of the clearest tells that it is not a peptide. At RxPepsDirect it is a 500 mcg capsule taken once daily in the morning. If a source is offering you injectable tesofensine, that alone is reason to question what you are being sold.
- Is tesofensine a GLP-1?
- No, and this is a separate confusion worth separating. A GLP-1 like semaglutide is a peptide that mimics an incretin hormone, acting on receptors in the gut and brain to slow gastric emptying and reduce appetite. Tesofensine is a small molecule acting on monoamine transporters in the central nervous system. Both reduce appetite, by entirely different routes, with entirely different side effect profiles. GLP-1 side effects are mostly gastrointestinal; tesofensine's are mostly cardiovascular and sleep-related.
- Is tesofensine a SARM or a stimulant?
- Not a SARM, which is a selective androgen receptor modulator and acts on an unrelated pathway. It is not formally classified as a stimulant either, though its pharmacology overlaps: by raising dopamine and noradrenaline tone it produces some stimulant-like effects, including the insomnia and heart rate elevation that appear in its side effect profile. Describing it as stimulant-adjacent is closer to accurate than any of the other labels commonly attached to it.
- Do I need a prescription for tesofensine?
- In the United States, yes. Tesofensine has no FDA approval and is not a dietary supplement, so it cannot lawfully be sold for human consumption as a consumer product. It reaches patients legitimately through a 503A compounding pharmacy against a prescription written by a licensed provider. The listings that sell it without one are labelled as research chemicals or as supplements, which is a labelling choice rather than a legal category the product actually fits.
Continue reading